CX-1739

CX-1739 is a drug that has been studied for its potential use in the treatment of cognitive disorders. It acts as a GABA_A receptor positive allosteric modulator and also inhibits the GABA transporter 1 (GAT1), which may contribute to its pharmacological effects.

Pharmacology

CX-1739 is a positive allosteric modulator of the GABA_A receptor, a type of protein that responds to the neurotransmitter gamma-aminobutyric acid (GABA). By enhancing the effects of GABA at this receptor, CX-1739 may increase the inhibitory effects of this neurotransmitter, potentially leading to sedative and anxiolytic effects.

In addition to its effects on the GABA_A receptor, CX-1739 also inhibits the GABA transporter 1 (GAT1). This transporter is responsible for the reuptake of GABA from the synaptic cleft, and its inhibition by CX-1739 could lead to increased levels of GABA in the brain.

Clinical significance

CX-1739 has been studied for its potential use in the treatment of cognitive disorders. However, as of 2021, it is not currently approved for use in any country.

See also

• GABA_A receptor
• GABA transporter 1
• Positive allosteric modulator

References

CX-1739 Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski